Last updated: 2026-09-09 05:05:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Seres Therapeutics, Inc. (MCRB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $5.58, with a market capitalization of $57.46M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.32 to $29.98. This page covers its latest market performance, valuation, price trends and company information.
$57.46M | |
$5.68 | |
$1,040.00 | |
$4.32 | |
$5.72 | |
34.30K | |
88.98K | |
-- | |
$29.98 | |
$4.32 | |
-- | |
-- |
Seres Therapeutics, Inc. (MCRB) last closed at $5.72 as of 2026-09-08 23:31:00, unchanged from the previous close of $5.72.
During the latest regular trading session, MCRB traded between $4.32 and $1,040.00, with a volume of 34.30K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Seres Therapeutics, Inc. (MCRB) moved from $4.95 to $5.58, representing a gain of 12.63% ($0.63).
The stock traded between $4.77 and $5.95 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 54.98 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 4.9%
MCRB is currently trading at $5.58, placing it 4.9% of the way from its 52-week low of $4.32 to its 52-week high of $29.98. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 66 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Seres Therapeutics, Inc. (MCRB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.